Therapeutic targets and corresponding detection methods of target therapy for non-small cell lung cancer / 中华检验医学杂志

ABSTRACT

Driver gene mutation is one of the most important cause of non-small cell lung cancer (NSCLC), as well as the drug target of target therapy. Patients with different driver mutations have different sensitivity to target therapy drug. So it is crucial to select target drug according to respective driver mutation. Nowadays more and more driver mutation detection come into clinical use for the guidance of NSCLC target therapy as well as more detection methods and commercial reagents were developed and utilized. Clinical and laboratory staff should be more cautious to select appropriate detection targets and reagents. Therefore, the relative target driver mutation and detection reagents in target therapy of NSCLC were reviewed in this paper, according to the China National Medical Products Administration, in order to provide reference for better selection of adequate methods and reagents as well as provide advice for personalized therapy of NSCLC patients.